stockrowCRISPR Therapeutics AG
CRSP Healthcare Biotechnology
CRISPR Therapeutics AG’s revenue for fiscal 2025 (year ended December 2025) was $3.5 million, down 90.6% from fiscal 2024.
- Revenue
- +1,325.1%
- EPS
- +1.55%
- Free cash flow
- −6.36%
Quarter to September 2026, against a year earlier
Follow CRSP
Alert me
CRISPR Therapeutics AG (CRSP) EPS (diluted)
CRISPR Therapeutics AG's EPS (diluted) for fiscal 2025 was −$6.47, compared with −$4.34 in fiscal 2024. Over the twelve months to 30 September 2026 it was −$4.74. Over the past ten years it has ranged from −$8.36 (fiscal 2022) to $4.70 (fiscal 2021); the current reading is higher than 18% of that period. CRISPR Therapeutics AG ranks 439th of 580 Biotechnology companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$6.47 | — |
| FY2024 | −$4.34 | — |
| FY2023 | −$1.94 | — |
| FY2022 | −$8.36 | — |
| FY2021 | $4.70 | — |
| FY2020 | −$5.29 | — |
| FY2019 | $1.17 | — |
| FY2018 | −$3.44 | — |
| FY2017 | −$1.71 | — |
| FY2016 | −$1.89 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | −$1.15 | — |
| Jun 2026 | −$0.94 | — |
| Mar 2026 | −$1.28 | — |
| Dec 2025 | −$1.37 | — |
| 39 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| EWTX Edgewise Therapeutics, Inc. compare | $8.19 |
| LEGN Legend Biotech Corporation Sponsored ADR compare | −$0.50 |
| ERAS Erasca, Inc. compare | −$0.95 |
| TVTX Travere Therapeutics, Inc. compare | −$1.29 |
| COGT Cogent Biosciences, Inc. compare | −$2.16 |
| DFTX Definium Therapeutics, Inc. compare | −$3.43 |
| DNTH Dianthus Therapeutics, Inc. compare | −$3.99 |
| CRSP CRISPR Therapeutics AG | −$4.74 |
| MANE Veradermics Incorporated compare | −$45.88 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on CRSP
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement